Chadbourne Wins Patent Office Victory for Synthon in Pexeva Case Chad…

Chadbourne Wins Patent Office Victory for Synthon in Pexeva Case

Chadbourne & Parke LLP recently represented Synthon Pharmaceuticals, Ltd. in a victory in its patent interference case in the U.S. Patent and Trademark Office over GlaxoSmithKline.

Synthon launched Pexeva this year in competition with GSK’s top-selling antidepressant Paxil®. On May 25, the Patent Office ruled that Synthon has sole rights to the patent on its drug and denied GSK’s claim for patent protection.

Last Dec. 30, Chadbourne won a settlement for Synthon right before a scheduled trial in a patent infringement lawsuit brought by GlaxoSmithKline. That settlement, coming on the eve of a January 12th trial date in federal court in Greensboro, NC, paved the way for the Chapel Hill, NC drug maker to begin selling Pexeva™, its competitor to GSK’s antidepressant medication Paxil®.

As in the court case, Chadbourne partner Mark Waddell was lead counsel for Synthon in the U.S. Patent Office case. He was assisted by Chadbourne associates Kathleen Gersh and Kimberly Muller.

Scroll to Top